Zoetis Inc. (ZTS)

US — Healthcare Sector
Peers: COR  REGN  IDXX  HLN  CI  ELV  BDX  ELAN  ARGX  TAK 

Automate Your Wheel Strategy on ZTS

With Tiblio's Option Bot, you can configure your own wheel strategy including ZTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZTS
  • Rev/Share 21.217
  • Book/Share 12.1879
  • PB 10.0436
  • Debt/Equity 1.3474
  • CurrentRatio 3.6431
  • ROIC 0.2108

 

  • MktCap 53945256326.0
  • FreeCF/Share 5.0576
  • PFCF 24.0827
  • PE 20.4509
  • Debt/Assets 0.4798
  • DivYield 0.0166
  • ROE 0.5356

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 2
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade ZTS Piper Sandler Overweight Neutral -- $135 Jan. 22, 2026
Downgrade ZTS BofA Securities Buy Neutral -- $135 Dec. 15, 2025
Initiation ZTS Barclays -- Equal Weight -- $136 Dec. 9, 2025
Initiation ZTS KeyBanc Capital Markets -- Sector Weight -- -- Nov. 21, 2025
Downgrade ZTS Leerink Partners Outperform Market Perform -- $155 July 17, 2025
Downgrade ZTS Stifel Buy Hold -- $160 June 18, 2025

News

Zoetis Reports Fourth Quarter and Full Year 2024 Results
ZTS
Published: February 13, 2025 by: Business Wire
Sentiment: Neutral

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025. The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter of 2024 increased 6% compared with the fourth quarter of 2023. Net income for the fourth quarter of 2024 was $581 mill.

Read More
image for news Zoetis Reports Fourth Quarter and Full Year 2024 Results

About Zoetis Inc. (ZTS)

  • IPO Date 2013-02-01
  • Website https://www.zoetis.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Kristin C. Peck
  • Employees 13800
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.